<DOC>
	<DOCNO>NCT00738829</DOCNO>
	<brief_summary>The aim study determine maximal tolerate dose level lenalidomide combine fludarabine/rituximab therapy patient previously untreated CD20-positive chronic lymphocytic leukemia . Following dose escalation phase lenalidomide give pre-determined maximum tolerate dose combination rituximab determine efficacy tolerability regimen .</brief_summary>
	<brief_title>Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine Untreated CLL</brief_title>
	<detailed_description>This non-randomized , multicenter , open-label , single-arm Phase I/II study patient previously untreated CD20-positive CLL . Phase I study evaluate maximal tolerate lenalidomide dose level combination fludarabine/rituximab chemoimmunotherapy 10 patient . Phase II determine efficacy use combination previously define maximal tolerate dose . Both phase follow maintenance phase evaluate tolerability possibility improve response quality .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>BCLL ( CD23+ , CD5+ , CD19+ , CD20+ ) Treatment indication accord NCI criterion Age &gt; = 18 yr No previous treatment CLL chemo , radio immunotherapy Life expectancy &gt; 6 month Written inform consent Women nonchildbearing potential woman childbearing potential men use effective contraception Active bacterial , viral fungal infection Positivity HIV , Hepatitis B C Reduce organ function bone marrow dysfunction due CLL Creatinine clearance 30 ml/min Patients medical condition require longterm use systemic corticosteroid study treatment Patients history severe cardiac disease Other know comorbidity potential dominate survival Transformation aggressive Bcell malignancy Known hypersensitivity humanise monoclonal antibody study drug Pregnant breastfeed woman Any coexist medical psychological condition would preclude participation study compromise ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>CLL</keyword>
	<keyword>untreated</keyword>
	<keyword>immune therapy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Fludarabine</keyword>
</DOC>